Reata Pharmaceuticals — Corporate Update (May 2018)
15 slides from Reata Pharmaceuticals's corporate update, May 25, 2018
Slide 1: Management call to discuss interim PHOENIX data
Management call to discuss interim phoenix data Exhibit 99.3
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statement
Slide 3: Bardoxolone Consistently Improved Kidney Function Through Unique MOA
Bowman’s Capsule (Parietal Epithelium) Tubule Filtrate Urine Blood Blood Normalized Glomerular Basement Membrane Normalized Endothelial Layer Bardoxolone Improved Fenestrations More Filtrate Urine Bowman’s Capsule (Parietal Epithelium) Tubule Filtrate Blood Blood Thickened Glomerular Basement Membra
Slide 4: CARDINAL Phase 2 Results Through Week 36
CARDINAL Phase 2 Results Through Week 36 Large, significant increases in eGFR observed through Week 36 High patient retention rate with 90% of patients on study after 9 months No discontinuations due to bardoxolone-related adverse events Patients followed for 2 years, retained benefit analysis at we
Slide 5: Bardoxolone Previously Improved Kidney Function in Three Forms of CKD
Disease Baseline eGFR Interim eGFR Increase Time point Long-term eGFR Increase Time point BEAM T2D CKD 32 12 Week 12 11 1 year CARDINAL Alport 54 13 Week 12 11 9 months LARIAT PAH 77 11 Week 16 11 2 years Bardoxolone Previously Improved Kidney Function in Three Forms of CKD 5 Alport Syndrome Glomeru
Slide 6: PHOENIX Study Design Overview
PHOENIX Study Design Overview Design Open-label, multi-center Phase 2 Study Enrollment size Approximately 100 patients; 25-30 patients in each of 4 cohorts Treatment Titration from 5 mg up to 20 mg or 30 mg daily for 12 weeks Key Eligibility Criteria Inclusion Exclusion Age ≥ 18 – 65 years old ADPKD
Slide 7: PHOENIX Baseline Characteristics
PHOENIX Baseline Characteristics Characteristic ADPKD (N=31) IgAN (N=26) Age, years (mean, SD) 47.4 ± 9.5 48.5 ± 9.5 Female (n,%) 21 (68%) 11 (42%) White/Caucasian (n,%) 25 (81%) 22 (85%) Baseline eGFR, mL/min/1.73 m2 (mean, SD) 47.7 ± 13.6 46.2 ± 12.6 Baseline ACR, mg/g (geometric mean) 44.3 104.0
Slide 8: Bard Significantly Improved eGFR in ADPKD Patients
Bard Significantly Improved eGFR in ADPKD Patients BL eGFR Change from Baseline in eGFR WK1 WK4 WK8 WK12 N 31 31 31 15 8 Mean ± SE 47.7 ± 2.4 3.5 ± 1.2 6.6 ± 0.9 9.3 ± 1.4 12.0 ± 1.4 95% CI (1.2 , 5.9) (4.8, 8.5 ) (6.5, 12.1 ) (9.2, 14.9 ) p-value - p=0.005 p<0.0001 p<0.0001 p<0.0001
Slide 9: Bard Significantly Improved eGFR in IgAN Patients
Bard Significantly Improved eGFR in IgAN Patients BL eGFR Change from Baseline in eGFR WK1 WK4 WK8 N 26 24 16 9 Mean ± SE 46.2 ± 2.5 4.0 ± 1.0 8.3 ± 1.1 8.4 ± 1.4 95% CI (2.0 , 5.9) (6.1, 10.6 ) (5.7, 11.1 ) p-value - p=0.0001 p<0.0001 p<0.0001 Data not shown beyond Week 8 since <25% of final data a
Slide 10: Summary of Albuminuria Data
Summary of Albuminuria Data Urinary albumin excretion, measured as ACR, unchanged in ADPKD cohort because PKD patients have an intact filtration barrier Patients had normal to near-normal levels of albuminuria at baseline and after treatment Increases in eGFR not expected to increase ACR because hea
Slide 11: Summary Blood Pressure and BNP
Summary Blood Pressure and BNP Blood pressure and BNP stable and within normal limits upon study entry No significant changes from baseline during treatment No evidence of overt fluid retention BNP Diastolic BP Systolic BP
Slide 12: Summary of Safety
Summary of Safety No treatment-related serious adverse events to date AEs to date have been mild to moderate in intensity Most commonly reported AE is muscle spasms, which is associated with reductions in CK *AEs reported in >2 patients Preferred Term ADPKD (N=31) Muscle spasms 12 (39%) Upper respir
Slide 13: Increases in eGFR Translated to Reduced Risk of Kidney Failure Outcomes in BEACON
Increases in eGFR Translated to Reduced Risk of Kidney Failure Outcomes in BEACON Post-hoc analyses from the BEACON study in T2D CKD showed bardoxolone methyl significantly reduced likelihood of kidney failure outcomes Composite of adjudicated ESRD, 30% decline, or eGFR < 15: HR=0.48, p<0.001 Select
Slide 14: Future Development and Commercialization
Future Development and Commercialization Large unmet medical need exists in ADPKD and IgA nephropathy In the U.S., ADPKD is the leading inheritable cause of CKD and the 4th leading cause of ESRD U.S. prevalence of ADPKD is approximately 400,000 people; 116,000 patients are diagnosed 50% of patients
Slide 15: s°s REATA saz
s°s REATA saz @OO barmaceuticars